	US 12,018,289 B2
	Vaccines based on mutant CALR and JAK2 and their uses
Ricardo Attar, Lawrenceville, NJ (US); Jason Dehart, San Diego, CA (US); Selina Khan, Leiden (NL); Vinod Krishna, Philadelphia, PA (US); Jenifer Lum, Castro Valley, CA (US); Christian Maine, San Diego, CA (US); Barbara Sanders, Amsterdam (NL); Manuel Alejandro Sepulveda, West Windsor, NJ (US); Patrick Wilkinson, Collegeville, PA (US); and Roland Zahn, Rijnsburg (NL)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Nov. 13, 2020, as Appl. No. 17/097,458.
Claims priority of provisional application 62/936,846, filed on Nov. 18, 2019.
Claims priority of provisional application 62/936,841, filed on Nov. 18, 2019.
Prior Publication US 2021/0222133 A1, Jul. 22, 2021
Int. Cl. C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C12N 15/86 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 45/06 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C12N 2750/14111 (2013.01)]

26 Claims

1. A polynucleotide encoding a polypeptide comprising the epitope sequences of:

(SEQ ID NO: 1)
MKDKQDEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQ

GWTE;

(SEQ ID NO: 2)
EEAEDNCRRMMRTK;

(SEQ ID NO: 5)
VLNYGVCFC;
and

(SEQ ID NO: 6)
FCGDENILV.